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Limited evidence exists on the clinical and economic burden of advanced fibrosis in patients with nonalcoholic fatty liver 
disease/nonalcoholic steatohepatitis (NAFLD/NASH) due to the invasiveness of liver biopsies for accurately staging liver 
disease. The fibrosis-4 (FIB-4) score allows for noninvasive assessment of liver fibrosis by using clinical and laboratory 
data alone. This study aimed to characterize the comorbidity burden, health care resource use (HCRU), and costs among 
patients with NAFLD/NASH with FIB-4-defined F3 (bridging fibrosis) and F4 (compensated cirrhosis) fibrosis. Using the 
Optum Research Database, a retrospective cohort study was conducted among 251,725 commercially insured adult patients 
with ≥1 NAFLD/NASH diagnosis from January 1, 2008, to August 31, 2016, and laboratory data required to calculate 
FIB-4 scores. Five criteria using varying FIB-4 score cutoffs were identified based on expert clinical opinion and published 
literature. Date of the first valid FIB-4 score marked the index date. Mean annual HCRU and costs were calculated during 
the pre-index and post-index periods. The prevalence of FIB-4-based F3 and F4 fibrosis was 0.40%-2.72% and 1.03%-
1.61%, respectively. Almost 50% of patients identified with FIB-4-based F3 or F4 had type 2 diabetes, cardiovascular dis-
ease, or renal impairment. Total all-cause health care costs increased significantly from pre-index to post-index for patients 
with FIB-4-based F3 fibrosis across most criteria (17%-29% increase) and patients with FIB-4-based F4 fibrosis across 
all criteria (47%-48% increase). Inpatient costs were the primary drivers of this increment. Conclusion: Significant increases 
in HCRU and costs were observed following FIB-4-based identification of F3 and F4 fibrosis among U.S. adults with 
NAFLD/NASH. These data suggest the importance of early identification and management of NAFLD/NASH that may 
halt or reduce the risk of disease progression and limit the underlying burden. (Hepatology Communications 2020;4:998-1011).
Nonalcoholic fatty liver disease (NAFLD) affects approximately 83.1 million American adults and contributes to significant mor-
bidity and mortality. NAFLD is the leading cause 
of chronic liver disease, and the presence of comor-
bidities, including obesity, insulin resistance, type 2 
diabetes (T2D), metabolic syndrome, hypertension, 
cardiovascular disease (CVD), and dyslipidemia, may 
promote the development of NAFLD/nonalcoholic 
steatohepatitis (NASH) and/or advance fibrosis 
progression.(1-4) Conversely, evidence suggests that 
NAFLD/NASH presence increases the risk of 
Abbreviations: ALT, alanine aminotransferase; APRI, aspartate transaminase to platelet ratio; AST, aspartate aminotransferase; CC, compensated 
cirrhosis; CVD, cardiovascular disease; DCC, decompensated cirrhosis; FIB-4, f ibrosis-4; HCC, hepatocellular carcinoma; HCRU, health care resource 
use; HIV, human immunodef iciency virus; ICD-9-CM/ICD-10-CM, International Classif ications of Diseases Ninth/Tenth Revisions Clinical 
Modif ication; LT, liver transplant; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PPPM, per patient per month; SD, 
standard deviation; T2D, type 2 diabetes.
Received December 20, 2019; accepted April 13, 2020.
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1524/suppinfo.
Supported by Gilead Sciences Inc.
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver 
Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use 
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modif ications or adaptations are 
made.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1524
Hepatology CommuniCations, Vol. 4, no. 7, 2020 GORDON ET AL.
999
developing these same comorbidities.(1-8) While most 
patients have NAFLD, the prevalence of NASH 
(steatohepatitis, inflammation, and hepatocyte injury 
with or without fibrosis) in the U.S. population is 
estimated at 2%-5%.(9-11) Patients with NASH are 
at an increased risk of progressing to compensated 
cirrhosis (CC) or decompensated cirrhosis (DCC) 
and additional complications, such as liver trans-
plant (LT)/liver failure and hepatocellular carcinoma 
(HCC).
The presence of fibrosis in NASH is the most 
important factor in determining disease progression 
and future complications.(12) Several studies observed 
that the presence of advanced fibrosis (stage 3 [F3 or 
bridging fibrosis] and stage 4 [F4 or CC]) in patients 
with NAFLD/NASH was associated with signifi-
cantly increased mortality risk,(13-16) which increased 
with advancing fibrosis stage.(13,16)
The differentiation between NAFLD and NASH 
is important to identify a high-risk group that 
may progress to fibrosis and cirrhosis. Liver biopsy 
remains the standard method; however, the use of 
biopsy in clinical practice is limited by invasiveness, 
cost, and potential for sampling error.(17,18) In a large 
community-based health care practice, only 0.9% of 
patients with a NAFLD/NASH diagnosis had a doc-
umented liver biopsy.(19) There are no known nonin-
vasive tests that can differentiate between fatty liver 
and steatohepatitis; however, noninvasive assessments 
of liver fibrosis using clinical and laboratory data 
(e.g., NAFLD fibrosis score,(20) aspartate aminotrans-
ferase (AST)-to-platelet ratio index [APRI],(21,22) 
BARD score,(23) fibrosis-4 score [FIB-4](24)) have 
been used to identify patients at risk of having F3 or 
F4,(10) potentially avoiding the need for liver biopsy 
and allowing for closer follow-up. Noninvasive assess-
ments also allow for sequential testing to observe 
disease progression. One method, FIB-4, uses an 
algorithm incorporating patient age, platelet count, 
AST, and alanine aminotransferase (ALT) levels to 
predict liver fibrosis. In one study, FIB-4 significantly 
outperformed other tests (Göteborg University cir-
rhosis index, AST to ALT ratio, APRI, BARD score, 
and cirrhosis discriminant score) for the prediction of 
advanced fibrosis versus lower fibrosis stages. Among 
patients with a FIB-4 index score below 1.30 or 
above 2.67, FIB-4 identified the absence or presence 
of advanced fibrosis with 90% and 80% accuracy, 
respectively.(25)
Due to the limited use of liver biopsy and absence 
of specific diagnosis codes for fibrosis stage, little is 
known on the economic and clinical burden of NASH 
in the United States, particularly among patients 
with advanced fibrosis. This study sought to identify 
patients with NAFLD/NASH with advanced fibro-
sis based on the noninvasive FIB-4 score and charac-
terize their comorbidity burden, health care resource 
use (HCRU), and costs. These data are critical to 
help guide resource planning from a public health 
perspective.
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Patients and Methods
Data souRCes
This retrospective cohort study was conducted 
using data from U.S. commercial health plan members 
in the Optum Research database, a nationally repre-
sentative database containing data on approximately 
13.5  million lives annually. Medical claims, phar-
macy claims, laboratory data, and enrollment infor-
mation were collected from July 1, 2007 to February 
28, 2017 (study period). International Classification 
of Diseases, Ninth and Tenth Revisions, Clinical 
Modification (ICD-9-CM/ICD-10-CM) diagnosis 
and procedure codes, Current Procedural Terminology 
version 4 procedure codes, health care common pro-
cedure coding system codes, and place of service codes 
were used to classify inpatient and outpatient services. 
Outpatient pharmacy claims comprised national drug 
codes for dispensed medications, quantity dispensed, 
and dose and days’ supply. Laboratory data were 
available for a subpopulation of the database, and the 
Standard Logical Observation Identifiers Names and 
Codes was used to define tests and results. Access to 
protected health information was not needed for this 
study, thus institutional review board approval or a 
waiver of authorization was not required.
stuDy sample seleCtion
Patients aged ≥18  years having ≥1 nondiagnostic 
medical claim with a primary or secondary diagnosis 
code for NAFLD and/or NASH (ICD-9-CM 571.8, 
571.9; ICD-10-CM K76.0, K75.81) from January 1, 
2008 to August 31, 2016 (identification period) were 
included in the study. NASH-specific ICD-9/10 
diagnosis codes were unavailable before September 
30, 2015, so diagnostic codes for NAFLD/NASH 
were used during this time period. The date of the 
first medical claim for NAFLD/NASH was the study 
entry date. Identified patients with NAFLD/NASH 
were required to have valid laboratory values (AST, 
ALT, and platelets) within 6 months of each other, 
sufficient to calculate a FIB-4 score during the identi-
fication period. The date of the first valid FIB-4 score 
was considered the index date. Additionally, contin-
uous enrollment in the health plan for ≥6  months 
before and ≥1  month after the study entry date was 
required.
Patients with a medical claim for other causes of 
liver disease (viral hepatitis [hepatitis A, B, C, D, E], 
toxic or autoimmune liver disease, cytomegaloviral 
infection, mumps, Wilson’s disease, Gaucher’s disease, 
lysosomal acid lipase deficiency, alcoholism or alcoholic 
liver disease, primary biliary/sclerosing cholangitis, 
or hemochromatosis) and human immunodeficiency 
virus (HIV) during the study period were excluded. 
Also excluded were those with ICD-9/10 diagnos-
tic codes for advanced liver disease (CC/DCC/LT/
HCC) before the F3/F4 index date. Patients with CC 
or DCC with evidence of a more severe liver disease 
stage within 90 days following the respective index 
date were assigned to the more severe stage to reduce 
the risk of misclassification.
FiB-4-BaseD iDentiFiCation oF 
aDVanCeD FiBRosis
Based on expert opinion and published literature, 
five criteria with varying FIB-4 cutoffs were used to 
categorize patients with F3/F4 fibrosis (Table 1).(26-28) 
If AST, ALT, and platelet laboratory values fell on 
separate dates, the date of the last laboratory value 
was used. For multiple scores on the same date, 
the lowest laboratory values were used to calculate 
FIB-4.
pre-index and post-index periods
The 6 months before the index date was considered 
the pre-index period. All eligible patients were fol-
lowed from the index date to the earliest of 6 months, 
taBle 1. CoHoRt iDentiFiCation BaseD on 
FiB-4 sCoRe
Criteria Cohort
FIB-4-Based 
Fibrosis Stage Cut-Off Values
Criterion 1(26) C1 FIB-4-based F3/F4 FIB-4 > 2.67
Criterion 2(27) C2 FIB-4-based F3 2.67 < FIB-4 ≤ 4.12
FIB-4-based F4* FIB-4 > 4.12
Criterion 3(28) C3 FIB-4-based F3 2.67 < FIB-4 ≤ 3.5
FIB-4-based F4† FIB-4 > 3.5
Criterion 4(28) C4 FIB-4-based F3 3.25 < FIB-4 ≤ 3.5
FIB-4-based F4† FIB-4 > 3.5
Criterion 5(27) C5 FIB-4-based F3 3.25 < FIB-4 ≤ 4.12
FIB-4-based F4* FIB-4 > 4.12
*Cohorts are identical.
†Cohorts are identical.
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progression to advanced liver disease (CC/DCC/
LT/HCC), end of coverage, or end of study period 
(post-index period).
stuDy measuRes
pre-index Demographics and Clinical 
Characteristics
Pre-index measures included patient demographics 
(age, sex, and geographic region), clinical characteris-
tics (APRI score,(29) Charlson comorbidity index,(30,31) 
comorbidities of interest), and cardiometabolic comor-
bidities (T2D, hypertension, CVD, hyperlipidemia, 
and renal impairment).
annual all-Cause HCRu
Mean per patient per month (PPPM) all-cause 
HCRU estimates were calculated during the pre- 
index and post-index periods. Mean PPPM estimates 
were annualized and included ambulatory (office and 
outpatient), emergency, and inpatient care. The mean 
number of outpatient visits by provider specialty was 
provided for the pre-index and post-index periods.
annual all-Cause Health Care Costs
All-cause health care costs were calculated during 
the pre-index and post-index periods as the mean 
PPPM combined health plan and patient-paid 
amounts adjusted for inflation between 2007 and 
2016, using the annual medical care component 
of the Consumer Price Index.(32) Mean PPPM 
estimates were annualized and included ambula-
tory (office, outpatient, and other nonemergency/ 
noninpatient costs), emergency, inpatient, and 
pharmacy costs.
statistiCal analysis
Means and standard deviations (SDs) were calcu-
lated for continuous variables, and frequencies and 
percentages were provided for categorical variables. 
Appropriate tests of statistical significance were 
used (two-sample t test for pre-index comparisons 
between different cohorts, paired t test for pre-index 
vs. post-index comparisons, McNemar’s test for pro-
portions). The percentage change in health care use 
was calculated. All analyses were performed using 
SAS 9.4 (SAS Institute, Inc., Cary, NC), with a sta-
tistical significance level of two-tailed P  <  0.05. A 
sensitivity analysis was conducted to calculate health 
care costs over a longer follow-up duration in which 
patients were followed until the earliest of progression 
to advanced liver disease (CC/DCC/LT/HCC), end 
of coverage, or end of the study period (post-index 
period).
Results
The percentage of patients with NAFLD/
NASH identified as FIB-4-based F3 and F4 varied 
depending on the FIB-4 criteria (C1-C5) applied. 
Among patients with NAFLD/NASH with suf-
ficient laboratory data to calculate a FIB-4 score, 
3.57% (n  =  3,251) were identified as FIB-4-based 
F3/F4, 0.40%-2.72% as F3, and 1.03%-1.61% as F4 
(Table 2).
pRe-inDeX DemogRapHiCs anD 
CliniCal CHaRaCteRistiCs
Mean age and sex were comparable across cohorts, 
with mean age ranging from 56.39 to 57.53 years 
and a slight minority being female (45.05%-50.37%) 
(Table 3). The APRI score was higher for FIB-4-
based F4 versus F3 cohorts.
The pre-index comorbidity burden was high and 
comparable among patients with FIB-4-based F3 
and F4 across all cohorts (Table 4). A majority had 
hypertension (F3 range, 57.30%-57.91%; F4 range, 
57.55%-58.57%) and hyperlipidemia (F3 range, 
51.69%-53.72%; F4 range, 50.27%-50.51%), more 
than one third had T2D (F3 range, 35.43%-36.64%; 
F4 range, 34.59%-34.93%), and approximately one 
fifth had CVD (F3 range, 20.47%-21.76%; F4 range, 
18.85%-19.07%). Approximately three-fourths and 
one-third of patients across all criteria with FIB-4-
based F3/F4, F3 and F4 had ≥1 and ≥3 cardiometa-
bolic comorbidities, respectively.
annual all-Cause HCRu
Health care resource use increased from pre- 
index to post-index for patients with FIB-4-based F3/F4 
fibrosis (C1) (Table 5). In the post-index period, 
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patients had significantly more inpatient admissions 
(0.36 vs. 0.24; P  =  0.002), inpatient stay days (2.76 
days vs. 1.92 days; P = 0.001), ambulatory visits (22.08 
vs. 17.52; P  <  0.001), and emergency visits (1.32 vs. 
1.08; P = 0.002).
Among patients with FIB-4-based F3, the num-
ber of ambulatory visits increased significantly from 
pre-index to post-index for all criteria (19%-26%). 
The mean number of inpatient stay days increased 
from pre-index to post-index for cohort C2 only. No 
significant differences were observed for cohorts C3, 
C4, or C5. Emergency visits also increased 10%-25% 
from pre-index to post-index among patients with 
FIB-4-based F3; however, this difference was only 
significant in cohort C2 (P = 0.021) and approached 
significance in cohort C3 (P = 0.052).
Among patients with FIB-4-based F4, the mean 
number of inpatient admissions increased 33% 
(P  ≤  0.005), ambulatory visits increased 29%-34% 
(P  <  0.001), and emergency visits increased 22% 
(P  ≤  0.027) from pre-index to post-index across all 
criteria. The mean number of inpatient stay days 
taBle 5. annual all-Cause HCRu
Pre-Index Mean (SD) Post-index Mean (SD) % Change P Value
Patients with FIB-4-based F3/F4 fibrosis
C1 F3/F4: FIB-4 > 2.67 (n = 3,251) Inpatient admissions 0.24 (1.08) 0.36 (1.44) 50% 0.002
Inpatient days 1.92 (0.82) 2.76 (1.23) 44% 0.001
Ambulatory visits 17.52 (18.36) 22.08 (19.68) 26% <0.001
Emergency visits 1.08 (3.60) 1.32 (4.80) 22% 0.002
Patients with FIB-4-based F3 fibrosis
C2 F3: 2.67 < FIB-4 ≤ 4.12 
(n = 2,482)
Inpatient admissions 0.24 (0.96) 0.36 (1.32) 50% 0.081
Inpatient days 1.44 (0.59) 2.04 (0.99) 42% 0.021
Ambulatory visits 17.16 (17.64) 20.76 (18.72) 21% <0.001
Emergency visits 1.20 (3.72) 1.32 (5.16) 10% 0.021
C3 F3: 2.67 < FIB-4 ≤ 3.5 
(n = 1,965)
Inpatient admissions 0.24 (0.96) 0.24 (1.20) 0% 0.509
Inpatient days 1.44 (0.58) 1.80 (0.82) 25% 0.233
Ambulatory visits 16.92 (17.40) 20.16 (18.12) 19% <0.001
Emergency visits 1.08 (3.60) 1.32 (5.28) 22% 0.052
C4 F3: 3.25 < FIB-4 ≤ 3.5 
(n = 363)
Inpatient admissions 0.24 (0.72) 0.24 (0.96) 0% 0.510
Inpatient days 1.68 (0.80) 0.84 (0.36) –50% 0.072
Ambulatory visits 16.32 (17.16) 20.52 (20.16) 26% <0.001
Emergency visits 0.96 (2.76) 1.20 (3.48) 25% 0.336
C5 F3: 3.25 < FIB-4 ≤ 4.12 
(n = 937)
Inpatient admissions 0.24 (0.84) 0.36 (1.32) 50% 0.317
Inpatient days 1.68 (0.68) 2.28 (1.15) 36% 0.211
Ambulatory visits 17.64 (18.12) 21.48 (19.80) 22% <0.001
Emergency visits 1.08 (3.48) 1.20 (4.20) 11% 0.180
Patients with FIB-4-based F4 fibrosis
C2/C5 F4: FIB-4 > 4.12 (n = 939) Inpatient admissions 0.36 (1.32) 0.48 (1.44) 33% 0.005
Inpatient days 3.24 (1.35) 4.44 (1.65) 37% 0.111
Ambulatory visits 18.96 (19.68) 25.44 (21.96) 34% <0.001
Emergency visits 1.08 (3.36) 1.32 (3.60) 22% 0.027
C3/C4 F4: FIB-4 > 3.5 (n = 1,463) Inpatient admissions 0.36 (1.20) 0.48 (1.44) 33% 0.004
Inpatient days 2.52 (1.06) 3.84 (1.58) 52% 0.008
Ambulatory visits 18.60 (19.32) 24.00 (21.00) 29% <0.001
Emergency visits 1.08 (3.48) 1.32 (3.96) 22% 0.024
FIB-4, Fibrosis-4; SD, standard deviation.
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increased 52% (P  =  0.008) from pre-index to post- 
index in cohort C3/C4.
Patients were most likely to visit a primary care 
provider for ambulatory visits as opposed to a gastro-
enterologist (Supporting Table S1).
annual all-Cause HealtH 
CaRe Costs
Total all-cause health care costs increased from 
pre-index to post-index by 37% ($28,983 vs. $39,658; 
P  <  0.001) among patients with FIB-4-based F3/F4 
(C1) (Fig. 1A). Inpatient costs were the primary driver 
of the increase in total all-cause health care costs in 
the post-index period.
Pre-index total all-cause health care costs were 
similar among patients with FIB-4-based F3 regard-
less of the criterion used, ranging from $21,827 to 
$27,427 (Fig. 1B). The main cost contributor across 
all cohorts was ambulatory services, accounting 
for approximately 53%-58% of total costs. In the 
post-index period, total all-cause health care costs in 
Fig. 1. Annual all-cause health care costs. (A) Patients with FIB-4-based F3/F4 fibrosis. (B) Patients with FIB-4-based F3 fibrosis. 
(C) Patients with FIB-4-based F4 fibrosis. Combined health plan and patient-paid amounts adjusted for inflation between 2006 and 
2016. *P < 0.05 for pre-index versus post-index. ↑ reflects increase from pre-index to post-index.
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patients with FIB-4-based F3 ranged from $24,150 
to $35,307, reflecting a significant increase across 
all cohorts (except C4), ranging from 11% to 29%. 
Inpatient costs were the primary drivers of this 
increase across all cohorts (except C3 and C4).
Patients with FIB-4-based F4 appeared to have 
slightly higher pre-index costs compared with 
patients with F3 ($37,101 for patients in cohort C2/
C5 and $33,836 for patients in cohort C3/C4) (Fig. 
1C). Similarly, post-index costs for patients with 
FIB-4-based F4 were slightly higher than patients 
with F3, ranging from $49,591 to $54,852. Total 
health care costs increased 47%-48% among patients 
with F4 from pre-index to post-index, with signifi-
cantly higher ambulatory costs, inpatient costs, and 
pharmacy costs, regardless of criteria used. Although 
ambulatory visits were the major cost contributors 
among all cohorts, inpatient costs had the largest 
increase from the pre-index to post-index periods 
(47%-48%).
In the sensitivity analysis, patient follow-up aver-
aged 17-20  months. Health care costs were slightly 
attenuated but remained consistent with costs 
presented over the 12-month follow-up period 
(Supporting Table S2).
Discussion
This study examined patients with NAFLD/
NASH with FIB-4-indentified F3 and F4 fibrosis 
within a U.S. payer system and provided real-world 
data on comorbidity profiles, all-cause HCRU, and 
associated costs. We found significant increases in 
HCRU and costs following FIB-4-based identifica-
tion of advanced fibrosis, particularly among patients 
with F4. Additionally, HCRU and costs increased 
with advancing liver fibrosis severity, highlighting the 
need for targeted interventions, particularly among 
patients with F3 to prevent progression to CC and 
CC-related complications.
An accurate estimate of the prevalence of patients 
with NAFLD/NASH and advanced fibrosis is neces-
sary to assess true disease burden. This study reported 
F3 prevalence at 0.40%-2.72% and F4 prevalence 
at 1.03%-1.61% among patients with NAFLD/
NASH; however, these estimates could very likely 
be under-reported compared to the true prevalence, 
given that only a proportion of diagnosed patients 
with NAFLD/NASH had available laboratory data 
and no definitive noninvasive test can accurately diag-
nose this condition. These results may also be limited 
in generalizability to other populations. As the study 
population is a convenience sample of patients in the 
database with available laboratory data, it is likely 
that those patients may have more comorbidities or 
advanced disease.
Patients with advanced fibrosis had high rates of 
cardiometabolic comorbidities, with similar rates 
observed in patients with F3 and F4. More than 
half of patients had ≥2 and approximately one 
third had ≥3 high-risk comorbid conditions (T2D, 
hypertension, hyperlipidemia, and renal disease). 
High rates of cardiometabolic comorbidities were 
also reported in a study of patients with NAFLD/
NASH with CC wherein 78.8% had hyperten-
sion, 52.6% had T2D, 48.9% had CVD, 47.5% 
had hyperlipidemia, 36.9% had obesity, and 32.3% 
had renal impairment.(33) The high prevalence of 
comorbidities likely contributed to the high rates of 
all-cause HCRU and costs as patients were treated 
for these conditions.
Patients with advanced fibrosis had high rates of 
HCRU and costs, with most patients with F3 averag-
ing more than $30,000 in annual health care costs and 
patients with F4 averaging approximately $50,000 in 
annual costs over the post-index period. While costs 
were similar among patients with F3 fibrosis regardless 
of criterion used, those meeting criterion 4, the most 
restrictive criterion, had slightly lower costs ($24,150), 
while patients meeting criteria 2 and 5, with a higher 
FIB-4 cutoff had slightly greater costs ($34,013 and 
$35,307, respectively). In a recent study among pri-
vately insured patients, those newly diagnosed with 
NAFLD incurred $7,804 in health care costs over the 
course of 1 year compared to $3,789 for patients with 
prevalent disease. Patients without NAFLD but with 
similar comorbidities had costs of $2,298 annually.(34) 
The higher costs in our study were likely due to more 
patients with advanced fibrosis and cirrhosis rather 
than newly diagnosed NAFLD, such as those in the 
Allen et al. study,(34) particularly because cardiomet-
abolic comorbidity rates were similar. Additionally, 
Allen et al. averaged costs over a much longer period, 
which likely resulted in lower cost estimates. Costs 
measured immediately following diagnosis are often 
much higher than costs averaged over a longer length 
of time.
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Patients categorized with F3 fibrosis had mean 
annual pre-index costs ranging from $21,828 to 
$28,983 and post-index costs ranging from $24,150 
to $39,658, depending on the FIB-4 definition used. 
Patients categorized as F4 had mean pre-index costs 
ranging from $28,983 to $37,101 and post-index costs 
ranging from $39,658 to $54,852.  Patients who had 
FIB-4-based F4 fibrosis had higher overall costs than 
patients with F3 with precirrhosis. A study by Canbay 
et al.(33) highlighted the importance of identifying 
patients before development of cirrhosis. Following a 
diagnosis of CC, the number of patients requiring an 
emergency visit doubled and the proportion of patients 
with a hospitalization rose from 40.9% to 66.9%. 
Mean annual all-cause health care costs increased 
93% after diagnosis ($14,600 vs. $7,600), with inpa-
tient costs more than tripling. Patients that progressed 
to end-stage liver disease had costs that rose even 
higher, primarily driven by a 411% increase in inpa-
tient costs.(33) Similarly, Boursier et al.(35) found that 
after diagnosis of CC, patients with NAFLD/NASH 
experienced an increase of 300% in the annual num-
ber of hospitalizations and an increase of over 250% 
in annual hospitalization costs. The higher health care 
costs over the post-index period in our study likely 
represented costs associated with diagnostic work-up 
and follow-up during disease progression. Health care 
costs would likely decrease further out from diagnosis 
until the patient progressed to more advanced disease 
or developed decompensation.
Fibrosis advances histologically with nonspecific 
symptoms, hence untreated advanced fibrosis may 
translate to more severe outcomes, leading to higher 
costs among patients with FIB-4-based F4. This 
observation could imply a missed opportunity to timely 
screen, diagnose, and manage patients before fibrosis 
progression. In the absence of better modalities, wide-
spread use of noninvasive tests to assess fibrosis in 
clinical practice may help to track fibrosis progression 
in a timely manner, with subsequent earlier identifi-
cation of patients with advanced fibrosis. Adoption of 
this practice may also provide point-of-service infor-
mation that reduces the need for liver biopsies to con-
firm fibrosis stage in cases of NAFLD/NASH. Our 
findings highlight the need for early fibrosis staging 
to identify patients with NAFLD/NASH, particularly 
those with F3 fibrosis, for targeted interventions to 
halt or reduce the risk of progression to cirrhosis and 
complications related to portal hypertension.
Claims data are subject to inherent limitations 
because they are based on disease and procedure pay-
ment codes. While these limitations do not substan-
tially reduce the strength of the study, they must be 
considered during interpretation of results. The iden-
tification of advanced liver diseases (CC/DCC/LT/
HCC) and other comorbidities (such as obesity) were 
limited to ICD-9/10-CM codes, which may have led 
to underestimation of the true number of patients. 
These codes merely reflect the claims submitted for 
reimbursement and are not necessarily confirmation 
of actual disease; however, use of these codes has been 
common practice in the literature. Additionally, ICD-
9-CM codes did not provide the level of granularity 
to distinguish NASH from NAFLD, but it is highly 
likely that study patients had NASH because other 
causes of liver disease were excluded and the popu-
lation was limited to those with biomarker-defined 
advanced fibrosis. Claims data also did not include 
historical or laboratory information regarding liver 
function or liver histology reports. Information on the 
amount of alcohol consumption was unavailable; how-
ever, because alcohol intake may affect the AST/ALT 
ratio, patients with a diagnosis of alcoholism were 
excluded from the study. Additionally, some patients 
who met the criteria for FIB-4-based F3 or F4 cutoffs 
may have been misclassified because abnormal AST 
and/or ALT values can occur for reasons other than 
fibrosis.(36) The stringent and comprehensive exclu-
sion criteria followed in the study, however, was meant 
to exclude patients with other causes of liver diseases, 
thereby preventing such bias.
Available laboratory information to calculate FIB-4 
was part of the inclusion criteria; however, laboratory 
data were only available for a subset of the population 
(30%-40%). Among patients with observable labora-
tory measures, the absence of liver biochemistries may 
have resulted in potential selection bias because rela-
tively sicker patients with certain comorbid or chronic 
disease (e.g., hyperthyroidism, hypothyroidism, ane-
mia, hyperlipidemia) may be more likely to obtain 
routine laboratory work-ups. The reason for ordering 
laboratory tests could not be determined from the 
claims data. It is unlikely that physicians screened for 
NAFLD/NASH using the FIB-4 algorithm, but rather 
the tests were ordered as part of routine care. While 
there are other noninvasive methods for the assess-
ment of liver fibrosis that may have higher positive 
predictive values or greater sensitivity (e.g., NAFLD 
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score), FIB-4 was chosen as it provided the most 
comprehensive method to accurately capture patients 
with advanced fibrosis based on laboratory data alone. 
Historically, FIB-4 was developed to assess liver fibro-
sis in patients with HIV and hepatitis C virus coinfec-
tion.(37) The fact that all the chosen cutoffs have not 
been validated within the NASH population (except 
criterion 1, FIB-4 >2.67) is a potential limitation. In 
a study validating FIB-4 for use in NAFLD, Shah 
et al.(25) found a FIB-4 score ≥2.67 had an 80% positive 
predictive value and a FIB-4 score of ≤1.30 had a 90% 
negative predictive value for advanced fibrosis. These 
results were corroborated in similar studies comparing 
the performance of noninvasive markers of advanced 
fibrosis in NASH(24,26,38-39); however, a recent study 
by Wong et al.(40) provided more robustness around 
the chosen cutoffs in this study. Nevertheless, future 
studies are needed to validate different FIB-4 cutoffs 
in the NAFLD/NASH population.
In conditions such as NAFLD/NASH where 
there are no available treatments, much of health 
care use is centered on diagnosis and follow-up. 
The calculation of annual HCRU and costs from 
PPPM values may have biased the annual estimates 
away from the null, as follow-up for individuals in 
the study ranged from 1 to 6 months and costs may 
have been greater in the first few months following 
diagnosis. Patients in this study were also required 
to have a minimum of 1 month of follow-up after 
the index date. This criterion was explicitly set to 
identify a more inclusive sample of patients and to 
reduce the risk of bias that may have been intro-
duced by requiring a longer follow-up that could 
result in a sample of healthier patients who did not 
die or progress to advanced liver disease (CC/DCC/
LT/HCC). Lastly, a retrospective study design was a 
limitation for this research question; however, given 
the issues associated with prospective studies (i.e., 
long follow-up times for a large number of patients, 
time-consuming, costly), it was more feasible to 
conduct a retrospective cohort study. Additional 
studies with multivariable models are needed to 
control for the confounding effects of demograph-
ics and comorbidities on HCRU and costs to better 
understand the drivers of this economic burden.
This study documented high rates of comorbidi-
ties, HCRU, and costs among patients with NAFLD/
NASH with FIB-4-based advanced fibrosis, reflect-
ing the economic burden and urgency to treat this 
population. The pre-index comorbidity burden was 
high and comparable across all cohorts, with almost 
50% of patients having T2D, CVD, or renal impair-
ment. Once identified as FIB-4-based F3 or F4, 
patients experienced significant increases in HCRU 
and health care costs, with inpatient costs being the 
major drivers of this increment. This indicates a 
missed opportunity to be diagnosed and treated in 
the early stages of liver disease. Further investigation 
also revealed that a significant minority of patients 
with FIB-4-identified F3 and F4 progressed to more 
advanced stages, leading to diagnoses of CC/DCC/
LT/HCC. Future research with longer follow-up time 
is needed to further delineate factors associated with 
real-world disease progression (e.g., weight attributed 
to T2D, age >50 years, increased ALT, hyperten-
sion)(41-44) to provide insight for targeting effective 
treatment strategies as they become available and 
for resource planning from a public health perspec-
tive given the huge clinical burden of patients with 
NASH. Future work is also needed to identify the 
utility of noninvasive tests in risk stratification of 
patients at earlier fibrosis stages for prevention and 
targeted interventions.
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